A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistemamagna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.
展开▼
